Cargando…
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients with MBC were enrolled in a first-line...
Autores principales: | Ciardiello, F, Troiani, T, Caputo, F, De Laurentiis, M, Tortora, G, Palmieri, G, De Vita, F, Diadema, M R, Orditura, M, Colantuoni, G, Gridelli, C, Catalano, G, De Placido, S, Bianco, A R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361320/ https://www.ncbi.nlm.nih.gov/pubmed/16685276 http://dx.doi.org/10.1038/sj.bjc.6603141 |
Ejemplares similares
-
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
por: De Vita, F, et al.
Publicado: (2005) -
Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011) -
Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
por: Ventriglia, J., et al.
Publicado: (2018) -
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass
por: Orditura, Michele, et al.
Publicado: (2007) -
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
por: Martinelli, E, et al.
Publicado: (2017)